TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2012

Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer.

Suresh S Ramalingam et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.